SUBSCRIBE

How do the biosimilar markets in the US and Europe compare?

 Posted 19/02/2021

Authors discuss how the biosimilar markets in the US and Europe compare in a report produced for the Biosimilars Council [1].

more
Canada approves infliximab biosimilar Remsima SC Biosimilars/News | Posted 19/02/2021
EU MedSoc 2016 Cover V15L30DG
Improving stakeholder understanding about biosi... Biosimilars/Research | Posted 19/02/2021
Innovent starts phase II trial for ipilimumab c... Biosimilars/News | Posted 19/02/2021
UK’s MHRA publishes guidance on licensing biosi... Guidelines | Posted 19/02/2021
Adherence improves long-term prognosis and medi... Generics/Research | Posted 19/02/2021
Biosimilar approvals and patent litigation in t... Biosimilars/General | Posted 19/02/2021
Problems with the tiered pricing policy for gen... Policies & Legislation | Posted 19/02/2021
Interchangeability, naming and pharmacovigilanc... Biosimilars/Research | Posted 12/02/2021
EMA recommends approval of adalimumab biosimila... Biosimilars/News | Posted 12/02/2021
EU MedSoc 2016 Cover V15L30DG
What can the US learn from the European biosimi... Reports | Posted 12/02/2021
Innovent makes deal for bevacizumab copy biolog... Pharma News | Posted 12/02/2021
Improving the understanding of biosimilars thro... Biosimilars/Research | Posted 12/02/2021
Anti-competitive strategic patenting by pharmac... Generics/Research | Posted 12/02/2021
FDA publishes report on areas of regulatory foc... Reports | Posted 12/02/2021
Canada approves insulin aspart biosimilar Trurapi Biosimilars/News | Posted 12/02/2021
ST002293
Regulatory issues related to quality of biosimi... Biosimilars/Research | Posted 05/02/2021
FDA includes generics of complex drugs in regul... Reports | Posted 05/02/2021
China extends indications for adalimumab and be... Biosimilars/News | Posted 05/02/2021
Understanding and minimizing injection-site pai... Biosimilars/Research | Posted 05/02/2021
Biosimilars policy considerations in the US Reports | Posted 05/02/2021
Canada approves three teriparatide biosimilars... Biosimilars/News | Posted 05/02/2021
Biocon and Lupin launch generic tacrolimus caps... Generics/News | Posted 05/02/2021
Partnerships formed and extended between Isu Ab... Pharma News | Posted 05/02/2021
Top 10 most read GaBI Online articles in 2020 Pharma News | Posted 29/01/2021
Interchangeability V18K30
Clinical evidence for interchangeability of bio... Biosimilars/Research | Posted 29/01/2021
EMA recommends approval of insulin aspart biosi... Biosimilars/News | Posted 29/01/2021
FDA approves rituximab biosimilar Riabni Biosimilars/News | Posted 29/01/2021
US biosimilars reimbursement: Medicare and 340B Reports | Posted 29/01/2021
Italy publishes new guidelines on pricing and r... Guidelines | Posted 29/01/2021
New generics company to offer low-cost versions... Generics/General | Posted 29/01/2021
EMA and EU medicines regulatory joint five-year... Policies & Legislation | Posted 29/01/2021
Biosimilars and lack of resources Biosimilars/Research | Posted 22/01/2021
EMA recommends approval of adalimumab and insul... Biosimilars/News | Posted 22/01/2021
How organizations worldwide are producing HTA r... Biosimilars/Research | Posted 22/01/2021
Generics applications under review by EMA – Jan... Generics/General | Posted 22/01/2021
Key considerations for payers, employers and pa... Reports | Posted 22/01/2021
Canada approves heparin biosimilars Redesca and... Biosimilars/News | Posted 22/01/2021
FDA increases transparency of biosimilar applic... Guidelines | Posted 22/01/2021
Samsung biosimilars: denosumab clinical trials... Biosimilars/General | Posted 22/01/2021
Biosimilars and availability of reference products Biosimilars/Research | Posted 15/01/2021
Biosimilars applications under review by EMA –... Biosimilars/General | Posted 15/01/2021
EC approval for pegfilgrastim biosimilar Nyvepria Biosimilars/News | Posted 15/01/2021
19646665_l
Influence of local policy measures and practice... Biosimilars/Research | Posted 15/01/2021
US guidance on proprietary names Guidelines | Posted 15/01/2021
Positive phase III results for sintilimab plus... Biosimilars/Research | Posted 15/01/2021
Perspectives of prescribing practices in public... Generics/Research | Posted 15/01/2021
Celltrion: Takeda acquisitions and new plant de... Pharma News | Posted 15/01/2021
Regulatory challenges with biosimilars Biosimilars/Research | Posted 08/01/2021
China approves adalimumab copy biological HLX03 Biosimilars/News | Posted 08/01/2021
more

NON-BIOLOGICAL COMPLEX DRUGS

FDA issues final guidance on liposome drug products Posted 27/04/2018

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft...

more


FDA approves 40 mg follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 09/03/2018
Mylan launches first follow-on glatiramer aceta... Non‐Biological Complex Drugs/News | Posted 15/02/2018
Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 04/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015
more

Country Focus

All countries

Sign up today to receive weekly news on the latest developments in generic and biosimilar medicines!

Generics News Research General

more

Biosimilars News Research General

more

More editorial sections